Page 3 - Polyphor Ltd News Today

Polyphor to extend period for its strategic evaluation by up to four weeks Polyphor AG / Key word(s): Statement 30-Jul-2021 / 07:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, July 30, 2021 Polyphor to extend period for its strategic evaluation by up to four weeks Polyphor AG (SIX: POLN) today provided an update regarding the recently announced evaluation ...

EQS-Adhoc: Polyphor AG: Polyphor gibt Update zur Zukunft der FORTRESS-Studie mit Balixafortide und kündigt erste Restrukturierungsschritte an Polyphor gibt Update zur Zukunft der FORTRESS-Studie mit Balixafortide und kündigt erste Restrukturierungsschritte an 16.07.2021 / 07:30 CET/CEST Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Allschwil, Schweiz, 16. Juli 2021 Polyphor gibt Update zur Zukunft de...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With ... Polyphor AGJune 28, 2021 GMT Co-primary endpoint of the study objective response rate (ORR) was not met The board of directors is undergoing a strategic assessment regarding the future of the company ALLSCHWIL, Switzerland, June 28, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN), a research driven clinical...

Polyphor AG / Key word(s): Study results28-Jun-2021 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Allschwil, Switzerland, June 28, 2021Polyphor provides update on the Phase III FORTRESS study of balixafortide in patients...

Neutrophil elastase inhibitator Market A new report titled, “Global neutrophil elastase inhibitator Market” has been added into its vast repository by

About Polyphor Polyphor is a research driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company’s leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered a...

EQS-Adhoc: Polyphor AG: Polyphor Annual General Meeting 2021 Polyphor Annual General Meeting 2021 06-Apr-2021 / 19:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, April 6, 2021 Polyphor Annual General Meeting 2021 Polyphor AG (SIX: POLN) today announced that its shareholders approved all proposals of the Board of Directors at the 24 th Annual General Meeting (AGM) with a signific...

Polyphor Annual General Meeting 2021 Search jobs Polyphor AG / Key word(s): AGMEGM 06-Apr-2021 / 19:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, April 6, 2021 Polyphor Annual General Meeting 2021 Polyphor AG (SIX: POLN) today announced that its shareholders approved all proposals of the Board of Directors at the 24 th Annual General Meeting (AGM) with a significant majority, w...

EQS-Adhoc: Polyphor AG: Polyphor publishes invitation to Annual General Meeting 2021 Polyphor publishes invitation to Annual General Meeting 2021 15-March-2021 / 07:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, March 15, 2021 Polyphor publishes invitation to Annual General Meeting 2021 - Pre-AGM information call on March 22, 2021 at 2PM CET - AGM to be held April 6, 2021 - Shar...

Polyphor AG / Key word(s): AGMEGM15-March-2021 / 07:30 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 KRThe issuer is solely responsible for the content of this announcement.Allschwil, Switzerland, March 15, 2021Polyphor publishes invitation to Annual General Meeting 2021- Pre-AGM information call on...